Table 1 Baseline characteristics of two groups’ patients
TACE-apatinib | TACE alone | P | |
|---|---|---|---|
Patients, n | 27 | 53 | |
Age(years), mean ± SD | 45.8±11.0 | 54.4 ± 11.9 | 0.654 |
Sex, n (%) | |||
Male | 23 (85.2) | 43 (81.1) | 0.453 |
Female | 4 (14.8) | 10 (18.9) | |
HBsAg expression | |||
Positive, n (%) | 26 (96.3) | 49 (92.5) | 0.659 |
Negative, n (%) | 1 (3.7) | 4 (7.5) | |
Child-Pugh class | |||
A, n (%) | 21 (77.8) | 48 (90.6) | 0.112 |
B, n (%) | 6 (22.2) | 5 (9.4) | |
AFP, ng/ml | |||
≤ 400, n (%) | 10 (37.0) | 23 (43.4) | 0.382 |
> 400, n (%) | 17 (63.0) | 30 (56.6) | |
Maximum HCC size(cm), mean ± SD | 12.11 ± 3.98 | 10.59 ± 4.30 | 0.419 |
Number of HCC foci | |||
1, n (%) | 3 (11.1) | 14 (26.4) | 0.137 |
2, n (%) | 1 (3.7) | 4 (7.5) | |
3, n (%) | 0 (0) | 3 (5.7) | |
> 3, n (%) | 23 (85.2) | 32 (60.4) | |
Extrahepatic metastasis, n (%) | 9 (39.1) | 16 (30.1) | 0.483 |
Vascular invasion, n (%) | |||
The number of TACE, mean ± SD | 22 (81.5) | 46 (86.8) | 0.374 |
2.19±1.04 | 2.34 ± 3.99 | 0.371 | |